GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Medicilon Inc (SHSE:688202) » Definitions » Gross Profit

Shanghai Medicilon (SHSE:688202) Gross Profit : ¥150 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Medicilon Gross Profit?

Shanghai Medicilon's gross profit for the three months ended in Mar. 2024 was ¥22 Mil. Shanghai Medicilon's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ¥150 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Shanghai Medicilon's gross profit for the three months ended in Mar. 2024 was ¥22 Mil. Shanghai Medicilon's Revenue for the three months ended in Mar. 2024 was ¥260 Mil. Therefore, Shanghai Medicilon's Gross Margin % for the quarter that ended in Mar. 2024 was 8.34%.

Shanghai Medicilon had a gross margin of 8.34% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

During the past 10 years, the highest Gross Margin % of Shanghai Medicilon was 45.34%. The lowest was 12.75%. And the median was 36.18%.

Warning Sign:

Shanghai Medicilon Inc gross margin has been in long-term decline. The average rate of decline per year is -4.7%.


Shanghai Medicilon Gross Profit Historical Data

The historical data trend for Shanghai Medicilon's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Medicilon Gross Profit Chart

Shanghai Medicilon Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 161.40 273.53 529.22 676.62 324.61

Shanghai Medicilon Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 196.54 149.53 27.39 -48.84 21.63

Competitive Comparison of Shanghai Medicilon's Gross Profit

For the Biotechnology subindustry, Shanghai Medicilon's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Medicilon's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Medicilon's Gross Profit distribution charts can be found below:

* The bar in red indicates where Shanghai Medicilon's Gross Profit falls into.



Shanghai Medicilon Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Shanghai Medicilon's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=1365.631 - 1041.022
=325

Shanghai Medicilon's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=259.506 - 237.876
=22

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥150 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Shanghai Medicilon's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=22 / 259.506
=8.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Shanghai Medicilon  (SHSE:688202) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Shanghai Medicilon had a gross margin of 8.34% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Shanghai Medicilon Gross Profit Related Terms

Thank you for viewing the detailed overview of Shanghai Medicilon's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Medicilon (SHSE:688202) Business Description

Traded in Other Exchanges
N/A
Address
Lane 67, Libing Road, Building 5, Pilot Free Trade Zone, Shanghai, CHN, 201299
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.

Shanghai Medicilon (SHSE:688202) Headlines

No Headlines